5 COVID Therapies Are Not Cost-Effective, According To NICE
Five COVID-19 therapies, including Merck & Co.'s antiviral tablet for high-risk patients, have been recommended for discontinuation by Britain's agency that decides whether medications...
IGBA Claims That 2022 WHO Biosimilar Guideline Boosts Access
According to the new whitepaper Embracing Science with Confidence: Adopting the Revised 2022 WHO Biosimilars Guideline from the International Generic and Biosimilar Medicines Association...
GHIT Fund Invests ¥790M In Ignored Tropical Disease Products
Two neglected tropical illnesses, lymphatic filariasis and onchocerciasis, will receive a combined investment of about 790-million-yen ($5.3 million) from the Global Health Innovative Technology...
To Reach Emission Goals, Seven Pharma CEOs Band Together
Seven CEOs of pharmaceutical companies, including GSK, AstraZeneca, Merck, Roche, Novo Nordisk, Samsung Biologics, and Sanofi, have launched a collaborative effort to meet short-term emission reduction...
Pharma In Africa Needs Indigenous Emphasis And Investment
The growth of the domestic pharmaceutical industry and a reduction in reliance on imports might be facilitated by funding AI-based research and development and...
EMA Backs Limitations On A Few Immune-Regulating Medications
Due to safety concerns, advisors to the European Medicines Agency on November 11th suggested restricting the use of a class of frequently prescribed anti-inflammatory...
Immune Omicron BQ Variations Are Increasing In The U.S.
As stated by the Centers for Disease Control and Prevention, Omicron subvariants will soon account for the bulk of new COVID infections in the...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...